Dr. Alexis Thompson

“Depending on the state that someone is in, some of the coverage may be more comprehensive than others,”

Dr. Alexis Thompson · said date not stated · reported 2026-10-16

Thompson acknowledged that coverage through the CMS Cell and Gene Therapy Access Model varies by state.

“The patients' priorities are actually a big part of really trying to figure out what the barriers to access are and how we overcome them,”

Dr. Alexis Thompson · said date not stated · reported 2026-10-16

Dr. Thompson discussed the importance of patient priorities in identifying and overcoming barriers to accessing gene therapies.